Trials / Active Not Recruiting
Active Not RecruitingNCT04848272
Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (estimated)
- Sponsor
- St Vincent's Institute of Medical Research · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1 study investigating safety of lanadelumab administration to patients with lung injury
Detailed description
This study will investigate the safety of inhibition of plasma kallikrein by lanadelumab administration in patients with lung injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lanadelumab | Monoclonal antibody that targets active plasma kallikrein |
| OTHER | Saline control | Saline control |
Timeline
- Start date
- 2021-08-09
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2021-04-19
- Last updated
- 2024-04-17
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04848272. Inclusion in this directory is not an endorsement.